Author

K. Kuramochi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

H. Ohashi· 3 shared K. Watashi· 3 shared M. Muramatsu· 3 shared M. Takeda· 3 shared T. Suzuki· 3 shared T. Wakita· 3 shared W. Saso· 3 shared K. Shionoya· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

H. Ohashi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

BiochemistrybioRxivOct 30, 2023

Functional and structural analysis of a cyclization domain in a cyclic beta-1,2-glucan synthase

N. Tanaka, R. Saito, K. Kobayashi…·T. Masaike

The paper functionally and structurally analyzes the cyclization domain of a cyclic β-1,2-glucan synthase, revealing it produces cyclic β-1,2-glucans through transglycosylation without hydrolysis and proposes it belongs to a new glycoside hydrolase family.

DOI 10.1007/s00253-024-13013-9

experimental assay

𝕏 PostBluesky

MicrobiologybioRxivJan 31, 2021

Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro

H. Ohashi, F. Wang, F. Stappenbeck…·K. Watashi

This study identifies oxysterol derivatives with anti-SARS-CoV-2 activity, showing that Oxy210 and Oxy232 inhibit viral replication by disrupting double membrane vesicles.

DOI 10.3390/ijms22063163

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivNov 19, 2020

Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro

K. Shionoya, M. Yamasaki, S. Iwanami…·K. Watashi

This study identifies Mefloquine as a potent in vitro entry inhibitor of SARS-CoV-2 with higher antiviral activity than Hydroxychloroquine.

DOI 10.3389/fmicb.2021.651403

statistical modeldrug response / drug discovery

𝕏 PostBluesky

MicrobiologybioRxivPreprintApr 14, 2020

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

H. Ohashi, K. Watashi, W. Saso…·T. Wakita

This study identifies a new multidrug combination treatment for COVID-19 using nelfinavir and cepharanthine, showing synergistic antiviral effects and improved disease control.

DOI 10.1101/2020.04.14.039925

experimental assaydrug response / drug discovery

𝕏 PostBluesky